Clinical efficacy of recombinant human thrombopoietin combined with glucocorticoids in the treatment of immune thrombocytopenia

Herein, we aimed to determine the clinical efficacy of recombinant human thrombopoietin (rhTPO) combined with glucocorticoids for treating immune thrombocytopenia (ITP). Clinical data of 87 patients with ITP admitted to our hospital were retrospectively analyzed, and patients were divided into two g...

Full description

Saved in:
Bibliographic Details
Published in:Hematology (Luxembourg) 2022-12, Vol.27 (1), p.1062-1068
Main Authors: Zhou, Jing-xin, Gao, Ling, Hu, Nan, Yan, Zhi-Ling, Tian, Chun-ying, Su, Jing, Qi, Ji-Jin, Yue, Jun-shuai, Ma, Wen-tong
Format: Article
Language:English
Subjects:
adverse effects
coagulation function
glucocorticoid
Immune thrombocytopenia
platelet count
recombinant human thrombopoietin
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Herein, we aimed to determine the clinical efficacy of recombinant human thrombopoietin (rhTPO) combined with glucocorticoids for treating immune thrombocytopenia (ITP). Clinical data of 87 patients with ITP admitted to our hospital were retrospectively analyzed, and patients were divided into two groups according to the treatment employed: 42 patients in the control group (CG) were prescribed glucocorticoids, and 45 patients in the study group (SG) received rhTPO combined with glucocorticoids. The total effective treatment rate in the SG (95.56%) was higher than that in the CG (76.19%) (P  50 × 10 9 /L faster and required fewer PLT transfusions than the CG (P 
ISSN:1607-8454
1607-8454
DOI:10.1080/16078454.2022.2121103